250 related articles for article (PubMed ID: 12532161)
1. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines.
Rissanen A; Lean M; Rössner S; Segal KR; Sjöström L
Int J Obes Relat Metab Disord; 2003 Jan; 27(1):103-9. PubMed ID: 12532161
[TBL] [Abstract][Full Text] [Related]
2. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
3. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
4. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
Krempf M; Louvet JP; Allanic H; Miloradovich T; Joubert JM; Attali JR
Int J Obes Relat Metab Disord; 2003 May; 27(5):591-7. PubMed ID: 12704403
[TBL] [Abstract][Full Text] [Related]
5. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
[TBL] [Abstract][Full Text] [Related]
6. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of orlistat for the treatment of overweight and obese patients in Ireland.
Lacey LA; Wolf A; O'shea D; Erny S; Ruof J
Int J Obes (Lond); 2005 Aug; 29(8):975-82. PubMed ID: 15852050
[TBL] [Abstract][Full Text] [Related]
8. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
9. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
10. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
[TBL] [Abstract][Full Text] [Related]
11. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.
Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA
Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049
[TBL] [Abstract][Full Text] [Related]
12. A one-year trial to assess the value of orlistat in the management of obesity.
James WP; Avenell A; Broom J; Whitehead J
Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
[TBL] [Abstract][Full Text] [Related]
13. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
Erdmann J; Lippl F; Klose G; Schusdziarra V
Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
[TBL] [Abstract][Full Text] [Related]
15. Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification.
Poston WS; Reeves RS; Haddock CK; Stormer S; Balasubramanyam A; Satterwhite O; Taylor JE; Foreyt JP
Int J Obes Relat Metab Disord; 2003 Dec; 27(12):1486-93. PubMed ID: 14634679
[TBL] [Abstract][Full Text] [Related]
16. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
17. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
[TBL] [Abstract][Full Text] [Related]
18. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
Rowe R; Cowx M; Poole C; McEwan P; Morgan C; Walker M
Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
[TBL] [Abstract][Full Text] [Related]
19. Orlistat.
Wong NN; Cheng-Lai A
Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255
[TBL] [Abstract][Full Text] [Related]
20. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up.
MacLaughlin HL; Cook SA; Kariyawasam D; Roseke M; van Niekerk M; Macdougall IC
Am J Kidney Dis; 2010 Jan; 55(1):69-76. PubMed ID: 19926371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
